Although not listed in the Table 3, a recent paper documented metabolic reprogramming and the predominance of several solute carrier genes (SLC12A5, SLC25A17 and SLC27A6) during acquired enzalutamide resistance in prostate cancer [64], emphasizing the importance of the SLC family members in prostate cancer. This evidence concerns the gene SLC27A6 and prostate cancer.